Syngene Intl drops on lowering FY25 guidance; Q3 PAT jumps 17% YoY 
(16:13, 24 Jan 2025)
The company reported 17.58% increase in consolidated net profit to ₹ 131.1 crore in Q3 FY25 as compared with ₹ 111.5 crore in Q3 FY24. Revenue from operations jumped 10.57% YoY to ₹ 943.7 core in Q3 FY25.

Profit before tax (PBT) increased 27.41% YoY to ₹ 180.8 crore in Q3 FY25. EBITDA stood at ₹ 302 crore, up 16% compared with ₹ 261 crore posted in corresponding quarter last year. EBITDA margin stood at 31.4% in during the quarter against 29.5% in Q3 FY24.

The company said that third quarter performance was marked by growth in the research services as well as CDMO business with increased traction in biologics. Development and Manufacturing Services delivered steady performance driven by biologics with repeat orders from existing customers and new collaborations on integrated projects that cover the scope from drug development to clinical stage manufacturing.

Growth observed this quarter indicates stabilizing market dynamics, particularly within the US biotech sector. However, the expected second-half recovery in demand has been delayed by approximately 8 to 12 weeks. Despite this delay, Syngene has returned to growth and anticipates continued momentum through Q4.

Consequently, the company projects single-digit revenue growth and flat PAT for the full year, with EBITDA guidance unchanged at around 30% for FY25. It earlier guided revenues in high single digits to low double digits for FY25.

Jonathan Hunt, managing director and chief executive officer, Syngene International, said, Syngene's third quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter.

Our Discovery Services division saw the initial 'China+1' pilot projects, with large and midsize pharma companies, starting to convert into longer term contracts. Now, our focus is on further business development and building the sales pipeline. The quarter also saw positive momentum in our CDMO division led by biologics. Growth in the quarter suggests that market dynamics, particularly in US biotech, are stabilising, albeit later than expected.'

Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.

Powered by Capital Market - Live News

No Details of this news available

Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018.

Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form.

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.

Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal,
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.